Service Hygiène et Epidémiologie, Hospices Civils de Lyon, Lyon, France
Public Health, Epidemiology & Evolutionary Ecology of Infectious Diseases (PHE3ID) team, Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
BMJ Open. 2024 Mar 19;14(3):e078504. doi: 10.1136/bmjopen-2023-078504.
Antimicrobial resistance (AMR) has become a significant public health threat. Without any interventions, it has been modelled that AMR will account for an estimated 10 million deaths annually by 2050, this mainly affects low/middle-income countries. AMR has a systemic negative perspective affecting the overall healthcare system down to the patient's personal outcome. In response to this issue, the WHO urged countries to provide antimicrobial stewardship programmes (ASPs). ASPs in hospitals are a vital component of national action plans for AMR, and have been shown to significantly reduce AMR, in particular in low-income countries such as Madagascar.As part of an ASP, AMR surveillance provides essential information needed to guide medical practice. We developed an AMR surveillance tool-Technique de Surveillance Actualisée de la Résistance aux Antimicrobiens (TSARA)-with the support of the Mérieux Foundation. TSARA combines bacteriological and clinical information to provide a better understanding of the scope and the effects of AMR in Madagascar, where no such surveillance tool exists.
A prospective, observational, hospital-based study was carried out for data collection using a standardised data collection tool, called TSARA deployed in 2023 in 10 hospitals in Madagascar participating in the national Malagasy laboratory network (Réseau des Laboratoires à Madagascar (RESAMAD)). Any hospitalised patient where the clinician decided to take a bacterial sample is included. As a prospective study, individual isolate-level data and antimicrobial susceptibility information on pathogens were collected routinely from the bacteriology laboratory and compiled with clinical information retrieved from face-to-face interviews with the patient and completed using medical records where necessary. Analysis of the local ecology, resistance rates and antibiotic prescription patterns were collected.
This protocol obtained ethical approval from the Malagasy Ethical Committee n°07-MSANP/SG/AGMED/CNPV/CERBM on 24 January 2023. Findings generated were shared with national health stakeholders, microbiologists, members of the RESAMAD network and the Malagasy academic society of infectious diseases.
抗菌药物耐药性(AMR)已成为一个重大的公共卫生威胁。如果不采取任何干预措施,据模型预测,到 2050 年,AMR 每年将导致约 1000 万人死亡,这主要影响中低收入国家。AMR 具有系统性的负面影响,影响整个医疗保健系统,直至影响患者的个人预后。为应对这一问题,世界卫生组织(WHO)敦促各国提供抗菌药物管理方案(ASPs)。医院中的 ASP 是国家抗 AMR 行动计划的重要组成部分,事实证明,ASP 可显著降低 AMR,尤其是在马达加斯加等低收入国家。作为 ASP 的一部分,抗菌药物耐药性监测提供了指导医疗实践所需的重要信息。在梅里埃基金会的支持下,我们开发了一种抗菌药物耐药性监测工具——Actualisée de la Résistance aux Antimicrobiens (TSARA)。TSARA 结合了细菌学和临床信息,更好地了解了 AMR 在马达加斯加的范围和影响,而该国尚无此类监测工具。
本研究为前瞻性、观察性、基于医院的研究,使用标准化数据收集工具(称为 TSARA)收集数据,该工具于 2023 年在马达加斯加参与国家马达加斯加实验室网络(Réseau des Laboratoires à Madagascar (RESAMAD))的 10 家医院中部署。纳入任何临床医生决定采集细菌样本的住院患者。作为一项前瞻性研究,从细菌学实验室常规收集个体分离物水平数据和病原体的抗菌药物敏感性信息,并与从与患者面对面访谈中检索到的临床信息以及必要时从病历中编译的信息进行编译。收集了当地生态、耐药率和抗生素处方模式的分析结果。
本研究方案于 2023 年 1 月 24 日获得了马达加斯加伦理委员会的批准(编号:07-MSANP/SG/AGMED/CNPV/CERBM)。研究结果与国家卫生利益相关者、微生物学家、RESAMAD 网络成员和马达加斯加传染病学术协会共享。